Twist Bioscience Partners With AWS to Enable AI-Driven Drug Testing Loop

Twist Bioscience is working with Amazon Web Services (AWS) to support Amazon Bio Discovery, a new platform that connects AI-driven drug design directly with laboratory testing. The collaboration places Twist as a core lab execution partner, responsible for synthesizing and validating molecules generated through the system’s AI models.

The platform links computational design with wet lab validation in a continuous loop. Scientists generate drug candidates using biological foundation models, send selected molecules to lab partners such as Twist for synthesis and testing, and feed results back into the system to improve subsequent designs. AWS said this approach replaces fragmented workflows that typically require manual coordination across multiple tools and vendors.

Twist’s role centers on converting AI-generated sequences into physical molecules and producing experimental data that informs the next iteration. The integration allows direct handoff from model output to lab validation, reducing delays between design and testing.

This model builds on a broader shift toward specialized AI systems trained on biological data rather than general-purpose models.